[Home]
[Full version]
Researchers create first chikungunya animal model
Feb 19 ,General Science
Researchers have developed the first animal model of the infection caused by chikungunya virus (CHIKV), an emerging arbovirus associated with large-scale epidemics that hit the Indian Ocean (especially the French Island of La Réunion) in 2005, later spreading to India, and Italy in 2007. Using this mouse model, scientists of the Institut Pasteur and INSERM determined which tissues and cells are infected by the virus in both the mild and severe forms of the disease it causes. They detail their findings in an article published February 15 in the open-access journal PLoS Pathogens.
The main symptoms of CHIKV —fever, joint and muscle pains, and skin rash— are now well known by the medical community and the general public. However, the pathophysiology of this infection remains poorly understood, notably the factors responsible for severe disease with neurological manifestations, which are mainly observed among newborns and the elderly.
The CHIKV animal model carries a deletion of a gene encoding one of the key proteins in the innate antiviral immune response. When only one of the two copies of the gene is deleted, the mice mimic the disease in its benign form. With both versions deleted, and therefore no ability to produce the protein, they constitute a model for the severe forms of the infection.
With this model, the researchers show how after an initial phase of viral replication in the liver, the infection extends to the joints, muscles and skin — where the symptoms materialize in humans. In the most severe cases, it then disseminates to the central nervous system. The model also allowed the investigators to study the mother-to-child transmission of the virus, a complication that was recorded for the first time during the La Réunion outbreak.
The development of this first mouse model provides chikungunya researchers with an experimental tool that sheds light on the pathophysiology of the infection, paving the way for future treatments and vaccine candidates against this emerging viral disease in vivo.
Citation: Couderc T, Chre´tien F, Schilte C, Disson O, Brigitte M, et al. (2008) A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4(2): e29. doi:10.1371/journal.ppat.0040029
Source: Public Library of Science
Related stories:
Acidifying oceans add urgency to CO2 cuts
It's not just about climate change anymore. Besides loading the atmosphere with heat-trapping greenhouse gases, human emissions of carbon dioxide have also begun to alter the chemistry of the ocean—often called the cradle of life on Earth. The ecological and economic consequences are difficult to predict but possibly calamitous, warn a team of chemical oceanographers in the July 4 issue of
Science, and halting the changes already underway will likely require even steeper cuts in carbon emissions than those currently proposed to curb climate change.
Drug reverses mental retardation caused by genetic disorder
UCLA mouse study offers hope for correcting how autism disrupts brain
UCLA researchers discovered that an FDA-approved drug reverses the brain dysfunction inflicted by a genetic disease called tuberous sclerosis complex (TSC). Because half of TSC patients also suffer from autism, the findings offer new hope for addressing learning disorders due to autism.
Nature Medicine publishes the findings in its online June 22 edition.
Discovery will assist treatment and research into fatal brain disorder
Research using newly developed Magnetic Resonance Imaging technology could soon allow clinicians to confirm Huntington's disease before symptoms appear in people who have the gene for the fatal brain disease.
Microenvironment a main driver of aggressive multi-lineage leukemia disease type
Research led by scientists at Cincinnati Children's Hospital Medical Center has revealed new clues into what causes different types of a particularly aggressive group of blood cancers known as mixed lineage leukemias (MLL) and how the disease might be treated, according to a study in the June 9 issue of
Cancer Cell.
Patients with heart failure often overestimate life expectancy
Many patients with heart failure have survival expectations that are significantly greater than clinical predictions, with younger patients and those with more severe disease more likely to overestimate their remaining life span, according to a study in the June 4 issue of JAMA.
Potential therapy discovered for hypophosphatasia, a congenital form of rickets
Researchers at the Burnham Institute for Medical Research, led by José Luis Millán, Ph.D., have demonstrated in mice the first successful use of enzyme replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal disease of genetic origin. This discovery lays the foundation for future clinical trials for HPP patients.
How defects in 1 gene cause 3 distinct and devastating human diseases
By studying heat-loving microbes, two research teams have gained new insight into how seemingly small differences in a single protein involved in DNA transcription and repair can lead to strikingly different genetic disorders in humans.
Researchers find smallpox drug may also target adenovirus
Scientists at Saint Louis University have made two key discoveries that could lead to the first-ever human testing of a drug to target the adenovirus, which causes a number of severe upper-respiratory infections and is one of many viruses that causes the common cold.
[Home]
[Full version]